Mats Wahlstrom Purchases 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom bought 5,000 shares of TriSalus Life Sciences stock in a transaction dated Friday, November 22nd. The shares were bought at an average cost of $4.55 per share, with a total value of $22,750.00. Following the completion of the acquisition, the director now owns 15,727 shares of the company’s stock, valued at $71,557.85. The trade was a 46.61 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Mats Wahlstrom also recently made the following trade(s):

• On Wednesday, November 20th, Mats Wahlstrom acquired 2,040 shares of TriSalus Life Sciences stock. The shares were bought at an average price of $4.16 per share, for a total transaction of $8,486.40.

TriSalus Life Sciences Stock Down 1.6 %

Shares of NASDAQ:TLSI opened at $4.25 on Thursday. The firm has a fifty day moving average of $4.23 and a two-hundred day moving average of $5.48. TriSalus Life Sciences, Inc. has a 12-month low of $3.61 and a 12-month high of $10.42. The firm has a market capitalization of $129.58 million, a P/E ratio of -1.71 and a beta of 0.49.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Roth Mkm initiated coverage on shares of TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 target price for the company. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective for the company. Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Finally, Oppenheimer started coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target on the stock. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Buy” and a consensus target price of $12.08.

Institutional Trading of TriSalus Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Duquesne Family Office LLC grew its stake in TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $1,184,000. Geode Capital Management LLC increased its holdings in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the last quarter. Wolverine Asset Management LLC bought a new position in TriSalus Life Sciences during the second quarter valued at approximately $240,000. Finally, MSD Partners L.P. acquired a new stake in TriSalus Life Sciences in the third quarter valued at approximately $184,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.